A basic research of nuclear imaging for prostate cancer with monoclonal antibody rm2

Yoko Hasegawa; Nobuyuki Oyama; Keiko Nagase; Osamu Yokoyama; Yasuhisa Fujibayashi; Takako Furukawa; Yoichi Arai; Seiichi Saito

A basic research of nuclear imaging for prostate cancer with monoclonal antibody rm2

Yoko Hasegawa, Nobuyuki Oyama, Keiko Nagase, Osamu Yokoyama, Yasuhisa Fujibayashi, Takako Furukawa, Yoichi Arai, Seiichi Saito

MED - Medical Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

An immunotracer, ¹²⁵Habeled RM2 (¹²⁵I-RM2) has been reported to be useful for nuclear imaging of prostate cancer. According to both in vitro and in vivo studies, the uptake of ¹²⁵I-RM2 in the prostate cancer cells, PC-3 and LNCaP, increased 6 hours after incubation with the tracer. This tracer uptake was blocked when the tumor cells were pretreated with unlabelled RM2. In the tumor-bearing mice, the tracer uptake was higher than that of muscle tissue at 72 hours after the tracer injection. ¹²⁵I-RM2 showed excellent prostate cancer cell targeting, both in vitro and in vivo. Accordingly, RM2 seems to be a candidate for use as a radioimmunotracer ligand for prostate cancer imaging.

Original language	English
Pages (from-to)	55-56
Number of pages	2
Journal	Nishinihon Journal of Urology
Volume	72
Issue number	2
Publication status	Published - 2010 Feb

Keywords

Immunotracer
Prostate cancer
RM2

ASJC Scopus subject areas

Urology

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Fingerprint Dive into the research topics of 'A basic research of nuclear imaging for prostate cancer with monoclonal antibody rm2'. Together they form a unique fingerprint.

Cite this

@article{c8242317ee2346bab1f52f122f351fc6,

title = "A basic research of nuclear imaging for prostate cancer with monoclonal antibody rm2",

abstract = "An immunotracer, 125Habeled RM2 (125I-RM2) has been reported to be useful for nuclear imaging of prostate cancer. According to both in vitro and in vivo studies, the uptake of 125I-RM2 in the prostate cancer cells, PC-3 and LNCaP, increased 6 hours after incubation with the tracer. This tracer uptake was blocked when the tumor cells were pretreated with unlabelled RM2. In the tumor-bearing mice, the tracer uptake was higher than that of muscle tissue at 72 hours after the tracer injection. 125I-RM2 showed excellent prostate cancer cell targeting, both in vitro and in vivo. Accordingly, RM2 seems to be a candidate for use as a radioimmunotracer ligand for prostate cancer imaging.",

keywords = "Immunotracer, Prostate cancer, RM2",

author = "Yoko Hasegawa and Nobuyuki Oyama and Keiko Nagase and Osamu Yokoyama and Yasuhisa Fujibayashi and Takako Furukawa and Yoichi Arai and Seiichi Saito",

year = "2010",

month = feb,

language = "English",

volume = "72",

pages = "55--56",

journal = "Nishinihon Journal of Urology",

issn = "0029-0726",

publisher = "Kyushu University, Faculty of Science",

number = "2",

}

TY - JOUR

T1 - A basic research of nuclear imaging for prostate cancer with monoclonal antibody rm2

AU - Hasegawa, Yoko

AU - Oyama, Nobuyuki

AU - Nagase, Keiko

AU - Yokoyama, Osamu

AU - Fujibayashi, Yasuhisa

AU - Furukawa, Takako

AU - Arai, Yoichi

AU - Saito, Seiichi

PY - 2010/2

Y1 - 2010/2

N2 - An immunotracer, 125Habeled RM2 (125I-RM2) has been reported to be useful for nuclear imaging of prostate cancer. According to both in vitro and in vivo studies, the uptake of 125I-RM2 in the prostate cancer cells, PC-3 and LNCaP, increased 6 hours after incubation with the tracer. This tracer uptake was blocked when the tumor cells were pretreated with unlabelled RM2. In the tumor-bearing mice, the tracer uptake was higher than that of muscle tissue at 72 hours after the tracer injection. 125I-RM2 showed excellent prostate cancer cell targeting, both in vitro and in vivo. Accordingly, RM2 seems to be a candidate for use as a radioimmunotracer ligand for prostate cancer imaging.

AB - An immunotracer, 125Habeled RM2 (125I-RM2) has been reported to be useful for nuclear imaging of prostate cancer. According to both in vitro and in vivo studies, the uptake of 125I-RM2 in the prostate cancer cells, PC-3 and LNCaP, increased 6 hours after incubation with the tracer. This tracer uptake was blocked when the tumor cells were pretreated with unlabelled RM2. In the tumor-bearing mice, the tracer uptake was higher than that of muscle tissue at 72 hours after the tracer injection. 125I-RM2 showed excellent prostate cancer cell targeting, both in vitro and in vivo. Accordingly, RM2 seems to be a candidate for use as a radioimmunotracer ligand for prostate cancer imaging.

KW - Immunotracer

KW - Prostate cancer

KW - RM2

UR - http://www.scopus.com/inward/record.url?scp=77749277463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77749277463&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77749277463

VL - 72

SP - 55

EP - 56

JO - Nishinihon Journal of Urology

JF - Nishinihon Journal of Urology

SN - 0029-0726

IS - 2

ER -

A basic research of nuclear imaging for prostate cancer with monoclonal antibody rm2

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Cite this